Omid Farokhzad, Seer CEO

Seer rais­es an­oth­er $55M and fi­nal­ly re­veals pro­teom­ic tech — can it hold up?

Two years ago, Omid Farokhzad left his promi­nent nano-med­i­cine lab at Boston’s Brigham and Women’s Hos­pi­tal and moved across the coun­try to found a start­up off tech­nol­o­gy that, he said, could change the field of pro­teomics — and, with it, parts of med­i­cine, agri­cul­ture and a range of fields.

To­day, Farokhzad has fi­nal­ly re­vealed what that tech­nol­o­gy is. In a Na­ture Com­mu­ni­ca­tions pa­per, he showed how his com­pa­ny, Seer, and their lead prod­uct, called the Pro­teo­graph, can use nanopar­ti­cles to an­a­lyze the pro­tein com­po­si­tions in a sin­gle blood sam­ple, like a fish­ing net web­bing the con­tents of a par­tic­u­lar swath of sea. Or — to use the com­pa­ny’s pre­ferred metaphor — like a se­quenc­ing ma­chine read­ing out the base pairs on a par­tic­u­lar strand of DNA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.